Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Sci Rep ; 9(1): 11602, 2019 08 12.
Article in English | MEDLINE | ID: mdl-31406134

ABSTRACT

Inconsistent findings between laboratories are hampering scientific progress and are of increasing public concern. Differences in laboratory environment is a known factor contributing to poor reproducibility of findings between research sites, and well-controlled multisite efforts are an important next step to identify the relevant factors needed to reduce variation in study outcome between laboratories. Through harmonization of apparatus, test protocol, and aligned and non-aligned environmental variables, the present study shows that behavioral pharmacological responses in Shank2 knockout (KO) rats, a model of synaptic dysfunction relevant to autism spectrum disorders, were highly replicable across three research centers. All three sites reliably observed a hyperactive and repetitive behavioral phenotype in KO rats compared to their wild-type littermates as well as a dose-dependent phenotype attenuation following acute injections of a selective mGluR1 antagonist. These results show that reproducibility in preclinical studies can be obtained and emphasizes the need for high quality and rigorous methodologies in scientific research. Considering the observed external validity, the present study also suggests mGluR1 as potential target for the treatment of autism spectrum disorders.


Subject(s)
Autism Spectrum Disorder/genetics , Disease Models, Animal , Nerve Tissue Proteins/genetics , Animals , Cross-Over Studies , Gene Knockdown Techniques , Male , Rats , Rats, Sprague-Dawley , Reproducibility of Results
2.
Front Mol Neurosci ; 11: 107, 2018.
Article in English | MEDLINE | ID: mdl-29970986

ABSTRACT

Mutations in the SHANK family of genes have been consistently identified in genetic and genomic screens of autism spectrum disorder (ASD). The functional overlap of SHANK with several other ASD-associated genes suggests synaptic dysfunction as a convergent mechanism of pathophysiology in ASD. Although many ASD-related mutations result in alterations to synaptic function, the nature of those dysfunctions and the consequential behavioral manifestations are highly variable when expressed in genetic mouse models. To investigate the phylogenetic conservation of phenotypes resultant of Shank2 loss-of-function in a translationally relevant animal model, we generated and characterized a novel transgenic rat with a targeted mutation of the Shank2 gene, enabling an evaluation of gene-associated phenotypes, the elucidation of complex behavioral phenotypes, and the characterization of potential translational biomarkers. The Shank2 loss-of-function mutation resulted in a notable phenotype of hyperactivity encompassing hypermotivation, increased locomotion, and repetitive behaviors. Mutant rats also expressed deficits in social behavior throughout development and in the acquisition of operant tasks. The hyperactive phenotype was associated with an upregulation of mGluR1 expression, increased dendritic branching, and enhanced long-term depression (LTD) in the striatum but opposing morphological and cellular alterations in the hippocampus (HP). Administration of the mGluR1 antagonist JNJ16259685 selectively normalized the expression of striatally mediated repetitive behaviors and physiology but had no effect on social deficits. Finally, Shank2 mutant animals also exhibited alterations in electroencephalography (EEG) spectral power and event-related potentials, which may serve as translatable EEG biomarkers of synaptopathic alterations. Our results show a novel hypermotivation phenotype that is unique to the rat model of Shank2 dysfunction, in addition to the traditional hyperactive and repetitive behaviors observed in mouse models. The hypermotivated and hyperactive phenotype is associated with striatal dysfunction, which should be explored further as a targetable mechanism for impairment in ASD.

3.
J Psychopharmacol ; 32(9): 1027-1036, 2018 09.
Article in English | MEDLINE | ID: mdl-29897000

ABSTRACT

Deficits in hippocampal-mediated pattern separation are one aspect of cognitive function affected in schizophrenia (SZ) or Alzheimer's disease (AD). To develop novel therapies, it is beneficial to explore this specific aspect of cognition preclinically. The location discrimination reversal (LDR) task is a hippocampal-dependent operant paradigm that evaluates spatial learning and cognitive flexibility using touchscreens. Here we assessed baseline performance as well as multimodal disease-relevant manipulations in mice. Mice were trained to discriminate between the locations of two images where the degree of separation impacted performance. Administration of putative pro-cognitive agents was unable to improve performance at narrow separation. Furthermore, a range of disease-relevant manipulations were characterized to assess whether performance could be impaired and restored. Pertinent to the cholinergic loss in AD, scopolamine (0.1 mg/kg) produced a disruption in LDR, which was attenuated by donepezil (1 mg/kg). Consistent with NMDA hypofunction in cognitive impairment associated with SZ, MK-801 (0.1 mg/kg) also disrupted performance; however, this deficit was not modified by rolipram. Microdeletion of genes associated with SZ (22q11) resulted in impaired performance, which was restored by rolipram (0.032 mg/kg). Since aging and inflammation affect cognition and are risk factors for AD, these aspects were also evaluated. Aged mice were slower to acquire the task than young mice and did not reach the same level of performance. A systemic inflammatory challenge (lipopolysaccharide (LPS), 1 mg/kg) produced prolonged (7 days) deficits in the LDR task. These data suggest that LDR task is a valuable platform for evaluating disease-relevant deficits in pattern separation and offers potential for identifying novel therapies.


Subject(s)
Aging/psychology , Conditioning, Operant/drug effects , Discrimination, Psychological/drug effects , Dizocilpine Maleate/pharmacology , Inflammation/psychology , Scopolamine/pharmacology , Animals , Dizocilpine Maleate/antagonists & inhibitors , Donepezil/pharmacology , Inflammation/chemically induced , Lipopolysaccharides , Male , Mice , Rolipram/pharmacology , Scopolamine/antagonists & inhibitors , Space Perception/drug effects
4.
Bioorg Med Chem Lett ; 22(18): 5876-84, 2012 Sep 15.
Article in English | MEDLINE | ID: mdl-22902656

ABSTRACT

The identification of highly potent and orally active triazines for the inhibition of PDE10A is reported. The new analogs exhibit low-nanomolar potency for PDE10A, demonstrate high selectivity against all other members of the PDE family, and show desired drug-like properties. Employing structure-based drug design approaches, we investigated the selectivity of PDE10A inhibitors against other known PDE isoforms, by methodically exploring the various sub-regions of the PDE10A ligand binding pocket. A systematic assessment of the ADME and pharmacokinetic properties of the newly synthesized compounds has led to the design of drug-like candidates with good brain permeability and desirable drug kinetics (t(1/2), bioavailability, clearance). Compound 66 was highly potent for PDE10A (IC(50)=1.4 nM), demonstrated high selectivity (>200×) for the other PDEs, and was efficacious in animal models of psychoses; reversal of MK-801 induced hyperactivity (MED=0.1mg/kg) and conditioned avoidance responding (CAR; ID(50)=0.2 mg/kg).


Subject(s)
Phosphodiesterase Inhibitors/pharmacology , Phosphoric Diester Hydrolases/metabolism , Triazines/pharmacology , Administration, Oral , Animals , Crystallography, X-Ray , Dizocilpine Maleate/antagonists & inhibitors , Dizocilpine Maleate/pharmacology , Dose-Response Relationship, Drug , Humans , Hyperkinesis/chemically induced , Hyperkinesis/drug therapy , Models, Molecular , Molecular Structure , Phosphodiesterase Inhibitors/administration & dosage , Phosphodiesterase Inhibitors/chemistry , Rats , Structure-Activity Relationship , Triazines/administration & dosage , Triazines/chemistry
5.
J Med Chem ; 54(21): 7621-38, 2011 Nov 10.
Article in English | MEDLINE | ID: mdl-21988093

ABSTRACT

The identification of highly potent and orally active phenylpyrazines for the inhibition of PDE10A is reported. The new analogues exhibit subnanomolar potency for PDE10A, demonstrate high selectivity against all other members of the PDE family, and show desired druglike properties. Employing structure-based drug design approaches, we methodically explored two key regions of the binding pocket of the PDE10A enzyme to alter the planarity of the parent compound 1 and optimize its affinity for PDE10A. Bulky substituents at the C9 position led to elimination of the mutagenicity of 1, while a crucial hydrogen bond interaction with Glu716 markedly enhanced its potency and selectivity. A systematic assessment of the ADME and PK properties of the new analogues led to druglike development candidates. One of the more potent compounds, 96, displayed an IC(50) for PDE10A of 0.7 nM and was active in predictive antipsychotic animal models.


Subject(s)
Antipsychotic Agents/chemical synthesis , Phosphodiesterase Inhibitors/chemical synthesis , Phosphoric Diester Hydrolases/metabolism , Pyrazines/chemical synthesis , Administration, Oral , Animals , Antipsychotic Agents/pharmacokinetics , Antipsychotic Agents/pharmacology , Avoidance Learning/drug effects , Binding Sites , Crystallography, X-Ray , Cyclic AMP/chemistry , Cyclic AMP/metabolism , Cyclic GMP/metabolism , Dogs , Female , Humans , Hydrolysis , Hyperkinesis/drug therapy , In Vitro Techniques , Isoenzymes/chemistry , Isoenzymes/metabolism , Ligands , Male , Mice , Microsomes/metabolism , Models, Molecular , Phosphodiesterase Inhibitors/pharmacokinetics , Phosphodiesterase Inhibitors/pharmacology , Phosphoric Diester Hydrolases/chemistry , Protein Conformation , Pyrazines/pharmacokinetics , Pyrazines/pharmacology , Rats , Rats, Sprague-Dawley , Rats, Wistar , Recombinant Proteins/chemistry , Stereoisomerism , Stereotyped Behavior/drug effects , Structure-Activity Relationship
6.
J Med Chem ; 53(6): 2521-7, 2010 Mar 25.
Article in English | MEDLINE | ID: mdl-20170099

ABSTRACT

Novel 5-cyclic amine-3-arylsulfonylindazoles were prepared, and several analogues within this class have been identified as high-affinity 5-HT(6) receptor ligands with improved pharmacokinetic and pharmacological properties. One selected example, 18b, showed good brain penetrability and a generally favorable pharmacokinetic profile with procognitive efficacy in the rat novel object recognition assay. The synthesis and structure-activity relationship of this potent class are discussed.


Subject(s)
Indazoles/metabolism , Receptors, Serotonin/metabolism , Serotonin Antagonists/metabolism , Sulfones/metabolism , Animals , Binding, Competitive , Brain/metabolism , Exploratory Behavior/drug effects , Habituation, Psychophysiologic/drug effects , Humans , Indazoles/chemistry , Indazoles/pharmacology , Models, Chemical , Molecular Structure , Rats , Receptor, Serotonin, 5-HT2B/chemistry , Receptor, Serotonin, 5-HT2B/metabolism , Receptors, Serotonin/chemistry , Recognition, Psychology/drug effects , Serotonin 5-HT2 Receptor Antagonists , Serotonin Antagonists/chemistry , Serotonin Antagonists/pharmacokinetics , Structure-Activity Relationship , Sulfones/chemistry , Sulfones/pharmacology
7.
J Pharmacol Exp Ther ; 332(1): 190-201, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19828876

ABSTRACT

The preclinical characterization of WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one] is described. In vitro binding and functional studies revealed highest affinity to the D(2) receptor (D(2L) K(i), 4.0 nM) and serotonin transporter (K(i), 7.1 nM), potent D(2) partial agonist activity (EC(50), 0.38 nM; E(max), 30%), and complete block of the serotonin transporter (IC(50), 56.4 nM). Consistent with this in vitro profile, WS-50030 (10 mg/kg/day, 21 days) significantly increased extracellular 5-HT in the rat medial prefrontal cortex, short-term WS-50030 treatment blocked apomorphine-induced climbing (ID(50), 0.51 mg/kg) in a dose range that produced minimal catalepsy in mice and induced low levels of contralateral rotation in rats with unilateral substantia nigra 6-hydroxydopamine lesions (10 mg/kg i.p.), a behavioral profile similar to that of the D(2) partial agonist aripiprazole. In a rat model predictive of antipsychotic-like activity, WS-50030 and aripiprazole reduced conditioned avoidance responding by 42 and 55% at 10 mg/kg, respectively. Despite aripiprazole's reported lack of effect on serotonin transporters, long-term treatment with aripiprazole or WS-50030 reversed olfactory bulbectomy-induced hyperactivity at doses that did not reduce activity in sham-operated rats, indicating antidepressant-like activity for both compounds. Despite possessing serotonin reuptake inhibitory activity in addition to D(2) receptor partial agonism, WS-50030 displays activity in preclinical models predictive of antipsychotic- and antidepressant efficacy similar to aripiprazole, suggesting potential efficacy of WS-50030 versus positive and negative symptoms of schizophrenia, comorbid mood symptoms, bipolar disorder, major depressive disorder, and treatment-resistant depression. Furthermore, WS-50030 provides a tool to further explore how combining these mechanisms might differentiate from other antipsychotics or antidepressants.


Subject(s)
Antidepressive Agents/pharmacology , Antipsychotic Agents/pharmacology , Benzoxazoles/pharmacology , Dopamine Agonists/pharmacology , Indenes/pharmacology , Receptors, Dopamine D2/agonists , Selective Serotonin Reuptake Inhibitors/pharmacology , Animals , Antidepressive Agents/chemistry , Antipsychotic Agents/chemistry , Avoidance Learning/drug effects , Behavior, Animal/drug effects , Benzoxazoles/chemistry , Brain/drug effects , Brain/metabolism , CHO Cells , Cricetinae , Cricetulus , Dopamine/metabolism , Dopamine Agonists/chemistry , Drug Evaluation, Preclinical , Humans , Indenes/chemistry , Male , Mice , Mice, Inbred Strains , Microdialysis , Motor Activity/drug effects , Protein Binding , Rats , Rats, Sprague-Dawley , Rats, Wistar , Serotonin/metabolism , Serotonin 5-HT1 Receptor Antagonists , Serotonin 5-HT2 Receptor Antagonists , Selective Serotonin Reuptake Inhibitors/chemistry , Transfection
8.
Neuropharmacology ; 58(1): 69-77, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19615387

ABSTRACT

The widely reported effects of oxytocin (OT) on CNS function has generated considerable interest in the therapeutic potential for targeting this system for a variety of human psychiatric diseases, including anxiety disorders, autism, schizophrenia, and depression. The utility of synthetic OT, as both a research tool and neurotherapeutic, is limited by the physiochemical properties inherent in most neuropeptides, notably its short half-life and poor blood brain barrier penetration. Subsequently, the discovery and development of non-peptide molecules that act as selective agonists of the oxytocin receptor (OTR) has been an important goal of the field. In this study, we report the receptor and behavioral pharmacology of WAY-267464, a first generation small-molecule OTR agonist. WAY-267464 is a high-affinity, potent, and selective (vs. V1a, V2, V1b) agonist of the OTR. In assays measuring both behavioral (four-plate test, elevated zero maze) and autonomic (stress-induced hyperthermia) parameters of the anxiety response, WAY-267464 exhibits an anxiolytic-like profile similar to OT. We have demonstrated that the anxiolytic-like profile of WAY-267464 is mediated through central sites of action. WAY-267464 also significantly reverses disruption in prepulse inhibition of the acoustic startle reflex induced by either MK-801 or amphetamine, similar to the antipsychotic-like effects previously reported for OT. Interestingly, in the mouse tail suspension test, WAY-267464 failed to produce changes in immobility that are seen with OT, raising the question of whether the antidepressant-like activity of OT may be working independently of the OTR. A selective OTR antagonist also failed to block the effects of OT on immobility in the TST. The significance of these findings for shaping the clinical development of OTR agonists is discussed.


Subject(s)
Anti-Anxiety Agents/pharmacology , Behavior, Animal/drug effects , Oxytocin/pharmacology , Receptors, Oxytocin/agonists , Acoustic Stimulation/adverse effects , Animals , Avoidance Learning/drug effects , Benzodiazepines/pharmacology , Benzodiazepines/therapeutic use , CHO Cells , Cricetinae , Cricetulus , Fever/drug therapy , Fever/etiology , Hindlimb Suspension/methods , Humans , Male , Maze Learning/drug effects , Mice , Mice, Inbred C57BL , Neural Inhibition/drug effects , Oxytocin/agonists , Protein Binding/drug effects , Pyrazoles/pharmacology , Pyrazoles/therapeutic use , Rats , Rats, Sprague-Dawley , Reflex, Startle/drug effects , Reflex, Startle/physiology , Stress, Psychological/complications
9.
Mol Cell Neurosci ; 42(4): 438-47, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19796684

ABSTRACT

In rodents, the orphan G protein-coupled receptor, Gpr88, is highly expressed in brain regions implicated in the pathophysiology of and is modulated by treatments for schizophrenia. We compared striatal function of Gpr88 knockout mice (Gpr88KOs) to wild-type mice using molecular, neurochemical and behavioral tests. Gpr88KOs lacked expression of Gpr88 in striatum, nucleus accumbens and layer IV of cortex. Gpr88KOs had normal striatal dopamine D2 receptor density and affinity and DARPP-32 expression but Gpr88KOs had higher basal striatal phosphorylated DARPP-32 Thr-34. In vivo microdialysis detected lower basal dopamine in Gpr88KOs while amphetamine-induced dopamine release was normal. Behaviorally, Gpr88KOs demonstrated disrupted prepulse inhibition of startle (PPI) and increased sensitivity to apomorphine-induced climbing and stereotypy (AICS) and amphetamine-stimulated locomotor activity. Antipsychotic administration to Gpr88KOs normalized the PPI deficit and blocked AICS. The modulatory role of Gpr88 in striatal dopamine function suggests it may be a new target for treatments for psychiatric disorders.


Subject(s)
Corpus Striatum/metabolism , Dopamine/metabolism , Receptors, G-Protein-Coupled/metabolism , Animals , Antipsychotic Agents/pharmacology , Apomorphine , Behavior, Animal/drug effects , Behavior, Animal/physiology , Brain/anatomy & histology , Brain/metabolism , Corpus Striatum/cytology , Dopamine Agonists/pharmacology , Dopamine Antagonists/pharmacology , Dopamine and cAMP-Regulated Phosphoprotein 32/metabolism , Female , Haloperidol/pharmacology , Humans , Male , Mice , Mice, Knockout , Motor Activity/drug effects , Motor Activity/physiology , Neuropsychological Tests , Receptors, Dopamine D2/metabolism , Receptors, G-Protein-Coupled/genetics , Reflex, Startle/drug effects , Reflex, Startle/physiology , Risperidone/pharmacology
10.
Bioorg Med Chem Lett ; 19(19): 5552-5, 2009 Oct 01.
Article in English | MEDLINE | ID: mdl-19720528

ABSTRACT

A 5-fluoro-tetrahydrocarbazole serotonin reuptake inhibitor (SRI) building block was combined with a variety of linkers and dopamine D2 receptor ligands in an attempt to identify potent D2 partial agonist/SRI molecules for treatment of schizophrenia. This approach has the potential to treat a broader range of symptoms compared to existing therapies. Selected compounds in this series demonstrate high affinity for both targets and D2 partial agonism in cell-based and in vivo assays.


Subject(s)
Carbazoles/chemistry , Dopamine Agonists/chemistry , Receptors, Dopamine D2/agonists , Schizophrenia/drug therapy , Selective Serotonin Reuptake Inhibitors/chemistry , Serotonin 5-HT1 Receptor Antagonists , Animals , Carbazoles/chemical synthesis , Carbazoles/pharmacology , Disease Models, Animal , Dopamine Agonists/chemical synthesis , Dopamine Agonists/pharmacology , Rats , Receptor, Serotonin, 5-HT1A/metabolism , Receptors, Dopamine D2/metabolism , Selective Serotonin Reuptake Inhibitors/chemical synthesis , Selective Serotonin Reuptake Inhibitors/pharmacology
11.
J Pharmacol Exp Ther ; 331(2): 574-90, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19661377

ABSTRACT

Following several recent reports that suggest that dual cAMP and cGMP phosphodiesterase 10A (PDE10A) inhibitors may present a novel mechanism to treat positive symptoms of schizophrenia, we sought to extend the preclinical characterization of two such compounds, papaverine [1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline] and MP-10 [2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline], in a variety of in vivo and in vitro assays. Both of these compounds were active in a range of antipsychotic models, antagonizing apomorphine-induced climbing in mice, inhibiting conditioned avoidance responding in both rats and mice, and blocking N-methyl-D-aspartate antagonist-induced deficits in prepulse inhibition of acoustic startle response in rats, while improving baseline sensory gating in mice, all of which strengthen previously reported observations. These compounds also demonstrated activity in several assays intended to probe negative symptoms and cognitive deficits, two disease domains that are underserved by current treatments, with both compounds showing an ability to increase sociality in BALB/cJ mice in the social approach/social avoidance assay, enhance social odor recognition in mice and, in the case of papaverine, improve novel object recognition in rats. Biochemical characterization of these compounds has shown that PDE10A inhibitors modulate both the dopamine D1-direct and D2-indirect striatal pathways and regulate the phosphorylation status of a panel of glutamate receptor subunits in the striatum. It is striking that PDE10A inhibition increased the phosphorylation of the (+/-)-alpha-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptor GluR1 subunit at residue serine 845 at the cell surface. Together, our results suggest that PDE10A inhibitors alleviate both dopaminergic and glutamatergic dysfunction thought to underlie schizophrenia, which may contribute to the broad-spectrum efficacy.


Subject(s)
Antipsychotic Agents , Cognition/drug effects , Phosphodiesterase Inhibitors/pharmacology , Phosphoric Diester Hydrolases/metabolism , Pyrazoles/pharmacology , Quinolines/pharmacology , Schizophrenic Psychology , Animals , Apomorphine/pharmacology , Avoidance Learning/drug effects , Catalepsy/chemically induced , Catalepsy/prevention & control , Dizocilpine Maleate/pharmacology , Excitatory Amino Acid Antagonists/pharmacology , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Neostriatum/drug effects , Neostriatum/metabolism , Rats , Rats, Sprague-Dawley , Reflex, Startle/drug effects , Reverse Transcriptase Polymerase Chain Reaction , Social Behavior , Stereotyped Behavior/drug effects
12.
Psychopharmacology (Berl) ; 204(1): 37-48, 2009 May.
Article in English | MEDLINE | ID: mdl-19107466

ABSTRACT

INTRODUCTION: 5-HT(2C) agonists, by decreasing mesolimbic dopamine without affecting nigrostriatal dopamine, are predicted to have antipsychotic efficacy with low extrapyramidal side effects (EPS). Combining 5-HT(2C) agonists with low doses of existing antipsychotics could increase treatment efficacy while reducing treatment liabilities such as EPS (typical antipsychotics), and the propensity for weight gain (atypical antipsychotics). OBJECTIVES: The objectives of these studies were to combine WAY-163909, a selective 5-HT(2C) agonist, with either the typical antipsychotic haloperidol, or the atypical antipsychotic clozapine, at doses that were ineffective on their own, with the expectation that a shift in potency in several rodent behavior models predictive of antipsychotic activity would occur. RESULTS AND DISCUSSION: In mice, co-administration of either haloperidol, or clozapine, produced a significant leftward shift in the ability of WAY-163909 to block apomorphine-induced climbing behavior, without any affect on apomorphine-induced stereotypy or an increased propensity for catalepsy. In the rat-conditioned avoidance model, WAY-163909 was combined with either haloperidol or clozapine at doses that individually produced reductions in avoidance response on the order of 10%, while the combination of WAY-163909 and either of the antipsychotics resulted in a greater than 70% reduction in avoidance, with no evidence of response failures, or pharmacokinetic interaction. CONCLUSION: Doses of either haloperidol or clozapine, that failed to antagonize an MK-801 induced deficit in prepulse inhibition, significantly attenuated the sensory gating deficit when combined with WAY-163909. Data support the notion that 5-HT(2C) receptor agonists, co-administered with other marketed antipsychotics, allow for dose sparing with a more favorable side-effect profile.


Subject(s)
Antipsychotic Agents/pharmacology , Avoidance Learning/drug effects , Azepines/pharmacology , Indoles/pharmacology , Serotonin 5-HT2 Receptor Agonists , Animals , Antipsychotic Agents/adverse effects , Antipsychotic Agents/therapeutic use , Apomorphine/antagonists & inhibitors , Azepines/adverse effects , Azepines/therapeutic use , Catalepsy/chemically induced , Catalepsy/drug therapy , Clozapine/adverse effects , Clozapine/pharmacology , Clozapine/therapeutic use , Dizocilpine Maleate/pharmacology , Drug Synergism , Drug Therapy, Combination , Haloperidol/adverse effects , Haloperidol/pharmacology , Haloperidol/therapeutic use , Indoles/adverse effects , Indoles/therapeutic use , Male , Mice , Rats , Rats, Sprague-Dawley , Reflex, Startle/drug effects , Stereotyped Behavior/drug effects
13.
J Pharmacol Exp Ther ; 327(3): 827-39, 2008 Dec.
Article in English | MEDLINE | ID: mdl-18753411

ABSTRACT

Positive allosteric modulators (PAMs) of metabotropic glutamate receptor subtype 5 (mGlu5) enhance N-methyl-d-aspartate receptor function and may represent a novel approach for the treatment of schizophrenia. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-methanone], a recently identified potent and selective mGlu5 PAM, increased (9-fold) the response to threshold concentration of glutamate (50 nM) in fluorometric Ca(2+) assays (EC(50) = 170 nM) in human embryonic kidney 293 cells expressing rat mGlu5. In the same system, ADX47273 dose-dependently shifted mGlu5 receptor glutamate response curve to the left (9-fold at 1 microM) and competed for binding of [(3)H]2-methyl-6-(phenylethynyl)pyridine (K(i) = 4.3 microM), but not [(3)H]quisqualate. In vivo, ADX47273 increased extracellular signal-regulated kinase and cAMP-responsive element-binding protein phosphorylation in hippocampus and prefrontal cortex, both of which are critical for glutamate-mediated signal transduction mechanisms. In models sensitive to antipsychotic drug treatment, ADX47273 reduced rat-conditioned avoidance responding [minimal effective dose (MED) = 30 mg/kg i.p.] and decreased mouse apomorphine-induced climbing (MED = 100 mg/kg i.p.), with little effect on stereotypy or catalepsy. Furthermore, ADX47273 blocked phencyclidine, apomorphine, and amphetamine-induced locomotor activities (MED = 100 mg/kg i.p.) in mice and decreased extracellular levels of dopamine in the nucleus accumbens, but not in the striatum, in rats. In cognition models, ADX47273 increased novel object recognition (MED = 1 mg/kg i.p.) and reduced impulsivity in the five-choice serial reaction time test (MED = 10 mg/kg i.p.) in rats. Taken together, these effects are consistent with the hypothesis that allosteric potentiation of mGlu5 may provide a novel approach for development of antipsychotic and procognitive agents.


Subject(s)
Allosteric Regulation/drug effects , Antipsychotic Agents/pharmacology , Cognition/drug effects , Oxadiazoles/pharmacology , Piperidines/pharmacology , Receptors, Metabotropic Glutamate/drug effects , Animals , Avoidance Learning/drug effects , Brain Chemistry/drug effects , Cell Line , Dose-Response Relationship, Drug , Drug Evaluation, Preclinical , Hippocampus/metabolism , Humans , Prefrontal Cortex/metabolism , Rats , Receptor, Metabotropic Glutamate 5
14.
Behav Brain Res ; 188(2): 412-5, 2008 Apr 09.
Article in English | MEDLINE | ID: mdl-18191235

ABSTRACT

Increased impulsivity is observed across a number of neuropsychiatric and neurodegenerative diseases. Preclinical evidence has demonstrated that antagonism of the serotonin 5-HT(2C) receptor may act to increase impulsivity, leading to the hypothesis that an agonist may exert reciprocal effects and attenuate impulsive behavior. The 5-HT(2C) agonist, WAY-163909, was evaluated in the present paper using a variable stimulus duration and inter-trial interval manipulation in the 5-choice serial reaction time test designed to increase impulsivity and decrease attention. WAY-163909 treatment selectively and dose-dependently decreased impulsivity suggesting that agonism of the 5-HT(2C) receptor may be useful for modulating impulsivity in disease states where impulsivity is a pathological feature.


Subject(s)
Azepines/administration & dosage , Choice Behavior/drug effects , Impulsive Behavior/drug therapy , Indoles/administration & dosage , Reaction Time/drug effects , Serotonin 5-HT2 Receptor Agonists , Animals , Behavior, Animal/drug effects , Dose-Response Relationship, Drug , Male , Rats , Rats, Long-Evans
15.
Prog Neuropsychopharmacol Biol Psychiatry ; 32(1): 34-41, 2008 Jan 01.
Article in English | MEDLINE | ID: mdl-17714843

ABSTRACT

Deficits in attention and response inhibition are apparent across several neurodegenerative and neuropsychiatric disorders for which current pharmacotherapy is inadequate. The 5-choice serial reaction time test (5-CSRTT), which originated from the continuous performance test (CPT) in humans, may serve as a useful translational assay for efficacy in these key behavioral domains. The selective norepinepherine reuptake inhibitor, atomoxetine, represents the first non-stimulant based drug approved for Attention Deficit Hyperactivity Disorder (ADHD) and has replaced methylphenidate (Ritalin) as the first line in pharmacotherapy for the treatment of ADHD. Methylphenidate and atomoxetine have different cortical and sub-cortical neurochemical signatures that could predict differences in cognitive and non-cognitive functions. The present experiments investigated the effects of acute methylphenidate and atomoxetine in male long Evans rats in the 5-choice serial reaction time (5CSRT) test that is hypothesized to serve as a model of vigilance and impulsivity behaviors associated with ADHD. Long Evans rats were trained to perform at 75% correct responses with fewer than 20% missed trials in the 5CSRT test (500 ms stimulus duration, 5 s inter-trial interval (ITI)). By varying the ITI (10, 7, 5, and 4 s) on drug test days, impulsivity (as defined by premature responses) was dramatically increased with a concomitant decrease in attention (percent correct). Subsequently, animals were treated with methylphenidate (2.5 and 5 mg/kg, i.p.) or atomoxetine (0.1, 0.5 and 1 mg/kg, i.p.) using this design. In Experiment 1, treatment with methylphenidate modestly improved overall attention but the highest dose of methylphenidate (5.0 mg/kg) significantly increased impulsivity. In contrast, treatment with atomoxetine induced a marked decrease in impulsivity whilst modestly improving overall attention. Interestingly, no effect was observed on measures of performance (e.g. motivation/sedation) with atomoxetine, whilst moderate hyperactivity (faster overall response latencies; magazine, correct, incorrect) was observed in the methylphenidate group. Those data suggest that the 5CSRT test can be used to differentiate stimulant and non-stimulant pharmacotherapies on measures of impulsivity.


Subject(s)
Adrenergic Uptake Inhibitors/pharmacology , Attention/drug effects , Central Nervous System Stimulants/pharmacology , Choice Behavior/drug effects , Impulsive Behavior/drug therapy , Methylphenidate/pharmacology , Propylamines/pharmacology , Reaction Time/drug effects , Animals , Atomoxetine Hydrochloride , Behavior, Animal/drug effects , Dose-Response Relationship, Drug , Male , Psychomotor Performance/drug effects , Rats , Rats, Long-Evans
SELECTION OF CITATIONS
SEARCH DETAIL
...